Endogenex, a medical device company, presented positive clinical trial data for its ReCET System, a novel endoscopic procedure for type 2 diabetes (T2D), at Digestive Disease Week 2025. The REGENT-1 Australia study demonstrated significant and sustained improvements in insulin sensitivity and beta cell function in patients with T2D after undergoing the procedure. The ReCET System uses pulsed electric field energy to treat the duodenum, the upper part of the small intestine, and regenerate healthy cells.
This development is potentially groundbreaking for T2D treatment. Current management strategies primarily focus on medication and lifestyle changes, but the ReCET System offers a potential one-time interventional approach. Improving insulin sensitivity and beta cell function directly addresses the core physiological defects underlying T2D, potentially offering a more effective and longer-lasting solution. This could translate to better blood sugar control, reduced reliance on medication, and a decreased risk of long-term complications for patients.
The REGENT-1 Australia study demonstrated procedural success in all cases without device- or procedure-related serious adverse events. The improvements in insulin sensitivity and beta cell function were observed at 12 weeks and persisted at 48 weeks, indicating a durable therapeutic effect. The data also suggests a dose-responsive relationship between the energy applied and the clinical outcomes.
The positive results from the REGENT-1 study strengthen the potential of the ReCET System to become a significant advancement in T2D care. Further studies will be crucial to validate these findings in larger populations and explore long-term efficacy and safety. If successful, this technology could shift the paradigm of T2D management towards a more curative approach, offering new hope for millions of people affected by this chronic disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
